Commitments and Contingencies (Details Narrative)						1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 23, 2024 USD ($)	Jun. 22, 2023 USD ($)	Feb. 05, 2021 USD ($)	Sep. 14, 2015 USD ($)	Dec. 24, 2013 USD ($)	Apr. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jan. 31, 2030 USD ($)	Dec. 31, 2023 USD ($)	Oct. 03, 2023 EUR (€)	Oct. 08, 2021 EUR (€)
Other Commitments [Line Items]
Research and development costs							$ 210,708	$ 427,457	$ 329,772	$ 616,542
Aggregate commitments expected							3,467,000		3,467,000
GEIS [Member]
Other Commitments [Line Items]
Amount related to milestone payment									684,652
NDA Consulting Corp [Member]
Other Commitments [Line Items]
Consulting and advisory fee					$ 4,000		4,000	4,000	8,000	8,000
Clinical Trial Agreements And Clinical Trial Monitoring Agreements [Member]
Other Commitments [Line Items]
Contractual commitment							3,614,000		3,614,000
Clinical Trial Agreements [Member]
Other Commitments [Line Items]
Contractual commitment							3,467,000		3,467,000
Clinical Trial Monitoring Agreements [Member]
Other Commitments [Line Items]
Contractual commitment							147,000		147,000
Total costs							8,228		8,228
Research and development costs							8,228
Aggregate commitments expected							18,000		18,000
Additional cost							72,000		72,000
Clinical Research Support Agreement [Member] | City of Hope [Member]
Other Commitments [Line Items]
Litigation settlement expense							78,015	0	78,015	69,001
Total costs							525,528		525,528
Collaboration Agreement [Member] | GEIS [Member]
Other Commitments [Line Items]
Inventory costs												$ 1,144,000
Research and development costs							0	268,829	0	268,829
Aggregate commitments expected							3,467,000		3,467,000
Collaboration Agreement [Member] | GEIS [Member] | Phase 1b [Member]
Other Commitments [Line Items]
Aggregate commitments expected							267,000		267,000
Collaboration Agreement [Member] | GEIS [Member] | Phase 2 [Member]
Other Commitments [Line Items]
Aggregate commitments expected							3,200,000		3,200,000
Collaboration Agreement [Member] | Bio Pharma Works LLC [Member]
Other Commitments [Line Items]
Consulting and advisory fee				$ 10,000
Reimbursed expense							7,200	30,000	27,200	60,000
Clinical Trial Research Agreement [Member]
Other Commitments [Line Items]
Research and development costs							0	6,000	0	12,000
Aggregate commitments expected							147,239		147,239
Work Order Agreement [Member]
Other Commitments [Line Items]
Total costs							27,595		27,595
Aggregate commitments expected							129,000		129,000
Work Order Agreement [Member] | City of Hope [Member]
Other Commitments [Line Items]
Total costs							87,681		87,681
Research and development costs			$ 335,000				4,500	5,687	9,000	11,240
Work Order Agreement [Member] | Theradex Systems, Inc. [Member]
Other Commitments [Line Items]
Research and development costs							7,203	6,250	12,733	6,250
Work cost		$ 153,000
Percentage of payment through services		72.00%
Percentage of payment through software		28.00%
License Agreement [Member]
Other Commitments [Line Items]
Non refundable license issue royalty	$ 50,000
Dosing of product	100,000
Payment for royalties	$ 1,225,000
Royalty percentage	5.00%
License Agreement [Member] | Minimum [Member]
Other Commitments [Line Items]
Non refundable license issue royalty						$ 50,000
License Agreement [Member] | Due Each January 1 [Member]
Other Commitments [Line Items]
Minimum annual royalty payable	$ 25,643					$ 25,643					$ 30,000
Licensing Agreements [Member]
Other Commitments [Line Items]
Research and development costs									60,569
Aggregate commitments expected							1,795,000		1,795,000
Research and development process costs							7,455		60,569
Stock based compensation								6,233		12,398
Development Collaboration Agreement [Member] | Netherlands Cancer Institute [Member]
Other Commitments [Line Items]
Research and development costs									619,640
Aggregate commitments expected							588,000		588,000				€ 500,000	€ 391,000
Advance amount related to milestone payment							67,119	53,178	134,084	105,382
MRI Global [Member]
Other Commitments [Line Items]
Research and development costs									325,085
Aggregate commitments expected							73,000		73,000
Advance amount related to milestone payment							$ 5,976	$ 5,210	$ 9,870	$ 9,583